Name(s) Target Manufacturer Status
Stivarga, regorafenib FLT1, KDR, FLT4, KIT, TEK, PDGFRB, PDGFRA, FGFR1, FGFR2, NTRK1, MAPK11, BRAF, ABL1, EPHA2, RAF1, RET, FRK Bayer AG FDA approved for: Colorectal Cancer, Gastrointestinal Stromal Tumor (GIST)

Clinical Trials

Trial Drug Status Phase
COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy [NCT01939223] Stivarga Recruiting Phase 3
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (CONSIGN) [NCT01538680] Stivarga Available Phase 3
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma [NCT02023333] Stivarga Recruiting Phase 2
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer [NCT02096354] RRx-001, Stivarga Recruiting Phase 2
Study of Ruxolitinib in Colorectal Cancer Patients [NCT02119676] Jakafi, Stivarga Recruiting Phase 2
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer [NCT01298570] Camptosar, Fluorouracil, Stivarga, leucovorin Recruiting Phase 2
Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer [NCT01896856] Camptosar, SGI-110, Stivarga Recruiting Phase 1/Phase 2
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination [NCT01973868] Erbitux, Stivarga Recruiting Phase 1
Regorafenib and Cetuximab in Patients With Advanced Malignancy [NCT02095054] Erbitux, Stivarga Recruiting Phase 1
A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer [NCT02024607] Avastin, BBI-608, Camptosar, Eloxatin, Fluorouracil, Stivarga, Xeloda, leucovorin Recruiting Phase 1
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer [NCT02116894] PF-03446962, Stivarga Not yet recruiting Phase 1
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment [NCT01853046] Stivarga Recruiting Phase 1